semaglutide pad A practice-changing trial': linked to key benefits for patients with diabetes pad #t2d #semaglutide | Patrick

The 2024 FDA removal of the black box cardiovascular warning from testosterone products, following the TRAVERSE trial's demonstration of cardiovascular safety, provides reassurance that combining TRT with retatrutide should not create additive cardiovascular risk for appropriate candidates

To view or add a comment, sign in Reposting this important studyadding 3 quick takeaways for patients

People with underlying metabolic conditions, thyroid disorders, or hormonal imbalances may need targeted medical treatment rather than general supplement support

Our L-glutathione capsules are easy to swallow, gentle on the stomach, and tasteless

GLP-1 therapy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)